Cure8 research brief
This paper links preclinical models and a short Phase 2a trial to show a candidate SIK2/SIK3 inhibitor (GLPG3970) produced anti-inflammatory and mucus-restoring signatures in IBD tissues. If findings hold in larger trials, this could offer a new therapeutic mechanism for UC and possibly Crohn’s disease.
Clinicians and researchers working on IBD drug development, patients and caregivers interested in emerging IBD therapies, and adults with UC or Crohn’s disease following investigational treatments.
This study reports translational preclinical and early clinical-phase evidence for GLPG3970, a selective SIK2/SIK3 inhibitor, tested across mouse colitis models, patient-derived intestinal organoids, ex vivo mucosal biopsies, and a short Phase 2a ulcerative colitis trial (NCT04577794).
Across models the drug was associated with increased epithelial mucus secretion and reduced inflammatory transcriptional signatures; ex vivo biopsy signatures aligned with gene-expression changes seen in the Phase 2 study.
The work is framed as supporting the use of patient-relevant experimental platforms to better predict clinical responses before larger trials.
The source is a Journal of Crohn’s & Colitis article summarizing integrated murine, ex vivo, organoid, and Phase 2a human data. The Phase 2 component was short (6 weeks) with small cohort sizes; larger randomized trials are needed to confirm efficacy and safety.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: Research Foundation Flanders - FWO-12A3026N
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study tests a new mechanism (TL1A inhibition) that may reduce inflammation and fibrosis in IBD. Positive phase 2b results suggest duvakitug could become another treatment option if later trials confirm benefit and...
A new antibody, duvakitug, showed higher remission/response rates than placebo in Phase 2b study data for both ulcerative colitis and Crohn’s disease, which could lead to a new treatment option if Phase 3 trials confirm...
This press release reports phase 2 evidence that a new experimental antibody (duvakitug) showed clinical, endoscopic, and histologic improvements in both UC and Crohn’s disease, which could lead to a new treatment option...
